Thomas Jefferson University

Jessica Teh

TitleAssoc Prof CHP
InstitutionThomas Jefferson University
DepartmentNursing - Undergraduate
Address233 S. 10th Street
Philadelphia PA 19107
Phone215-503-1491
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kadamb R, Anton ML, Purwin TJ, Seeneevassen L, Chua V, Waltrich F, Teh JLF, Nieto MA, Sato T, Terai M, Roman SR, De Koning L, Zheng D, Aplin AE, Aguirre-Ghiso JA. Lineage commitment pathways epigenetically oppose oncogenic Gaq/11-YAP1 signaling in dormant disseminated uveal melanoma. bioRxiv. 2025 Jan 28. PMID: 38496663.
      Citations:    
    2. Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, B?k?s M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res. 2024 Aug 15; 30(16):3549-3563. PMID: 38819400.
      Citations:    
    3. Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, Wunberg T, Zoephel A, Fu SC, Teh JL, B?ttcher J, Pototschnig N, Schachinger F, Schipany K, Lieb S, Vellano CP, O'Connell JC, Mendes RL, Moll J, Petronczki M, Heffernan TP, Pearson M, McConnell DB, Kraut N. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov. 2021 01; 11(1):142-157. PMID: 32816843.
      Citations:    
    4. Teh JLF, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunol Res. 2020 09; 8(9):1114-1121. PMID: 32661093.
      Citations:    
    5. Teh JLF, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso J, Aplin AE. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Mol Cancer Ther. 2020 08; 19(8):1719-1726. PMID: 32430489.
      Citations:    
    6. Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. J Invest Dermatol. 2020 11; 140(11):2242-2252.e7. PMID: 32389536.
      Citations:    
    7. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 02; 11(2). PMID: 30610113.
      Citations:    
    8. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 Dec; 8(12):1654. PMID: 30510016.
      Citations:    
    9. Teh JLF, Aplin AE. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. Clin Cancer Res. 2019 02 01; 25(3):921-927. PMID: 30287548.
      Citations:    
    10. Teh JLF, Aplin AE. Playing the Melanoma Endgame. Clin Cancer Res. 2018 10 01; 24(19):4629-4630. PMID: 29769205.
      Citations:    
    11. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567. PMID: 29496665.
      Citations:    
    12. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581. PMID: 29496664.
      Citations:    
    13. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res. 2016 09 15; 76(18):5455-66. PMID: 27488531.
      Citations:    
    14. Teh JL. Frizzled with age: an opportunity for 'gerontological medicine'. Pigment Cell Melanoma Res. 2016 09; 29(5):488-9. PMID: 27223582.
      Citations:    
    15. Teh JL, Shah R, Shin SS, Wen Y, Mehnert JM, Goydos J, Chen S. Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. Pigment Cell Melanoma Res. 2014 Jul; 27(4):621-9. PMID: 24628914.
      Citations:    
    16. Teh JL, Chen S. Glutamatergic signaling in cellular transformation. Pigment Cell Melanoma Res. 2012 May; 25(3):331-42. PMID: 22273393.
      Citations:    
    Teh's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (95)
    Explore
    _
    Co-Authors (13)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _